Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University spinout Argonaut Therapeutics is developing cancer drugs that reprogram cancer cells to undergo the body's natural process of cell death, shrinking tumours.

Drugs © Oleksii Fedorenko - Shutterstock

The company will focus on treatments for colorectal cancer and lymphoma.

Argonaut has raised seed funding from investment company Oxford Sciences Innovation to develop and test a set of drug candidates, as well as biomarkers that allow physicians to determine which patients are most likely to respond well to the new drugs.

Argonaut founder Professor Nick La Thangue is Chair of Cancer Biology at the University of Oxford. He said: 'Cancer drugs are relatively ineffective in as many as 70% of patients, in part due to genetic variations between patients. The demand for precision, personalised medicine is increasing. It is a cost-effective way of detecting disease earlier and it allows us to tailor therapies for each patient.

Read more

Similar stories

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.

Accidental awareness in obstetric surgery under general anaesthesia more frequent than expected

General Research

The largest ever study of awareness during obstetric general anaesthesia shows around 1 in 250 women may be affected, and some may experience long-term psychological harm.